Roche buys US biotech firm InterMune for £5bn

Filling syringes

Related Stories

Swiss pharmaceutical giant Roche has said it will buy maker of lung disease therapies InterMune for $8.3bn (£5bn).

Intermune, which is based in Brisbane, California, makes a medicine for idiopathic pulmonary fibrosis, a deadly disease which scars the lungs.

The deal is the latest in a string of mergers in the drugs sector.

It is also the largest by Roche since 2009 when it bought the remainder of Genentech for about $47bn.

Pharmaceutical mergers

Roche will pay $78 per share in InterMune, which is a premium of 38% on top of the value of the shares at the end of last week.

Recent deals in the drug sector include US drug firm AbbVie's purchase of the UK pharmaceutical company Shire for £32bn.

UK High Street chemist Alliance Boots was bought up by US pharmacy giant Walgreens in an agreement earlier this month.

In May, pharmaceutical company Pfizer dropped a bid for UK company AstraZeneca.

More on This Story

Related Stories

From other news sites

* May require registration or subscription

More Business stories

RSS

Features

From BBC Capital

Programmes

  • StudentsClick Watch

    Could a new social network help tailor lessons to students’ needs and spot when they fall behind?

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.